Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)

NCT02649361 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

164

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Anlotinib
DRUG: Placebo

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.